Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells

PURPOSE: Ongoing clinical trials show limited efficacy for Chimeric antigen receptor (CAR) T treatment for acute myeloid leukemia (AML). The aim of this study was to identify potential causes of the reported limited efficacy from CAR-T therapies against AML. EXPERIMENTAL DESIGN: We generated CAR-T c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nian, Zhigang, Zheng, Xiaohu, Dou, Yingchao, Du, Xianghui, Zhou, Li, Fu, Binqing, Sun, Rui, Tian, Zhigang, Wei, Haiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401534/
https://www.ncbi.nlm.nih.gov/pubmed/34233960
http://dx.doi.org/10.1158/1078-0432.CCR-21-0452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401534/
https://www.ncbi.nlm.nih.gov/pubmed/34233960
http://dx.doi.org/10.1158/1078-0432.CCR-21-0452

Ejemplares similares